
follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
report record revenu full year billion billion respect
revenu grew driven primarili spinraza
compani ad six clinic program neurosci pipelin
report posit phase data amyotroph later sclerosi al
cambridg mass januari -- biogen inc today report full year fourth quarter
execut well strateg prioriti financi object said michel vounatso
biogen chief execut offic made signific progress develop expand pipelin well
advanc multipl modal potenti deliv new therapi patient also report solid revenu growth
year led continu strong global penetr spinraza signific gain biosimilar busi
resili core ms busi believ strong base busi includ deep diversifi
neurosci pipelin posit well take advantag opportun us alway remain
focus alloc capit effici appropri object maxim return sharehold
long term
full year total revenu billion increas versu prior year
full year multipl sclerosi ms revenu includ million royalti sale ocrevu
rel stabl versu prior year billion
fourth quarter ms revenu includ million royalti sale ocrevu grew
versu prior year billion
full year revenu growth driven primarili continu global launch spinraza contribut
billion revenu compar million prior year
full year net incom dilut earn per share ep attribut inc billion
respect compar billion respect prior year
full year net incom dilut ep attribut inc neg impact
billion respect due transit toll tax re-measur net defer tax asset relat
 corpor tax reform legisl
full year non-gaap net incom dilut ep attribut inc billion
respect compar billion respect prior year
reconcili non- full year quarterli financi result found tabl end
news releas
shown strong momentum build depth core growth area beyond alzheim diseas
continu build multipl franchis within neurosci mr vounatso continu posit data
al highlight potenti leverag groundbreak scienc address previous untreat diseas
exemplifi strategi build depth neuromuscular diseas movement disord next
month expect sever import data readout across clinic program multipl sclerosi progress
supranuclear palsi alzheim diseas
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
biogen idec discov develop deliv patient world-wide innov therapi treatment
neurodegen diseas hemophilia autoimmun disord found world oldest
independ biotechnolog compani fortun compani billion annual revenu
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
global biopharmaceut compani develop deliv therapi patient
sever life-threaten diseas also ultra-rar alexion first commerci product soliri
eculizumab world first approv termin complement inhibitor today soliri approv nearli
countri treatment patient paroxysm nocturn hemoglobinuria pnh us european
union japan countri treatment patient atyp hemolyt urem syndrom ahu
discov develop manufactur deliv innov human therapeut use tool like advanc
human genet compani focus area high unmet medic need leverag biolog
manufactur expertis strive solut improv health outcom grown world
largest independ biotechnolog compani reach million patient around world develop
pipelin medicin breakaway potenti
biomarin found develop commerci innov biopharmaceut seriou diseas
medic condit compani four approv product naglazym galsulfas product wholli
develop commerci biomarin aldurazym laronidas develop joint ventur
genzym corpor kuvan sapropterin dihydrochlorid tablet develop partnership merck serono
divis merck kgaa darmstadt germani firdaps amifampridin approv
european commiss treatment lambert eaton myasthen syndrom
celgen global biopharmaceut compani discov develop commerci product treatment
cancer sever immun inflammatori condit clinic trial major medic
center use compound celgen
gilead research-bas biopharmaceut compani discov develop commerci innov medicin
area unmet medic need gilead product pipelin investig drug includ treatment
hiv/aid liver diseas seriou respiratori cardiovascular condit cancer inflamm market
product includ number categori first includ first complet treatment regimen hiv infect
avail once-daili singl pill first oral antiretrovir pill avail reduc risk acquir hiv
infect certain high-risk adult
regeneron lead scienc technolog compani deliv life-transform medicin seriou diseas
found physician-scientist nearli year ago compani science-driven approach result four
fda-approv medicin numer product candid rang diseas includ ophthalmolog
rheumatoid arthriti atop dermat asthma pain cancer infecti diseas
seattl genet biotechnolog compani focus develop commerci innov empow
antibody-bas therapi treatment cancer industri leader antibody-drug conjug adc
technolog design har target abil monoclon antibodi deliv cell-kil agent directli
cancer cell adc intend spare non-target cell thu reduc mani toxic effect tradit
chemotherapi potenti enhanc antitumor activ addit one market product advanc
deep product pipelin address signific unmet medic need
seattl genet found headquart bothel washington suburb seattl
compani complet initi public offer march trade nasdaq stock market
symbol compani employe passion help peopl live cancer
shire lead global biotechnolog compani focus serv peopl rare diseas highli
special condit strive develop best-in-class product mani avail
storag disord gastrointestin intern medicin endocrin hereditari angioedema grow
franchis oncolog
vertex global biotechnolog compani discov develop commerci innov new medicin
treat seriou diseas found cambridg vertex today research develop site
commerci offic us canada europ australia four year row scienc magazin name
vertex one top employ life scienc
unit state largest market biopharmaceut account around third global market
world leader biopharmaceut accord pharmaceut research manufactur
associ phrma firm conduct half world pharmaceut billion hold
intellectu properti right new medicin overal econom impact biopharmaceut industri
 economi substanti industri account trillion econom output repres
percent total output total econom impact includ billion revenu
biopharmaceut busi billion supplier worker spend
peopl work biopharmaceut industri unit state across broad rang
occup includ scientif research technic support manufactur directli indirectli industri
support million job across unit state industri requir highly-skil educ
workforc administr level includ ph scientist third job sector key
unit state one world support domest environ develop
commerci pharmaceut minim market barrier strength includ intellectu properti
system reward innov patent data protect science-bas regulatori system
consid rigor world largest scientif research base foster academ institut
decad govern research fund robust capit market unit state attract major
global ventur capit invest start-up biopharmaceut enterpris
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
